161P: Metabolic factors were associated with the outcome of gemcitabine-treated patients with advanced NSCLC identified by high through-put liquid-chip

Abstract

Background: Gemcitabine is one of the most frequently prescribed chemotherapy regimen for patients with advanced NSCLC. There is an urgent but un-met need to develop the prognostic biomarkers for the regimen. We reasoned the metabolic factors might be associated with the prognosis of this regimen. Methods: This study was a prospective, exploratory, registered trial (ChiCTR-POC-15007228). Newly-diagnosed, chemotherapynaïve patients with advanced NSCLC who were prescribed with gemcitabine chemotherapy (cisplatin or carboplatin) were enrolled. Blood was sampling before the initiation of the chemotherapy. The metabolic factors were determined by liquidchip (FLEXMAP 3D). The ERCC1 and RRM1 were detected by commercially available real-time PCR kits. The sera gemcitabine concentration was measured with HPLC. The primary end-point was OS.